JP2722214B2 - Eel disease treatment - Google Patents
Eel disease treatmentInfo
- Publication number
- JP2722214B2 JP2722214B2 JP63208837A JP20883788A JP2722214B2 JP 2722214 B2 JP2722214 B2 JP 2722214B2 JP 63208837 A JP63208837 A JP 63208837A JP 20883788 A JP20883788 A JP 20883788A JP 2722214 B2 JP2722214 B2 JP 2722214B2
- Authority
- JP
- Japan
- Prior art keywords
- eel
- eels
- disease treatment
- present
- chlorite
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
Classifications
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A40/00—Adaptation technologies in agriculture, forestry, livestock or agroalimentary production
- Y02A40/80—Adaptation technologies in agriculture, forestry, livestock or agroalimentary production in fisheries management
- Y02A40/81—Aquaculture, e.g. of fish
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Farming Of Fish And Shellfish (AREA)
Description
【発明の詳細な説明】 〔産業上の利用分野〕 本発明は新規なウナギ疾病治療剤、更に詳細には、細
菌性エラ病に対し卓越した効果を有するウナギ疾病治療
剤に関する。Description: FIELD OF THE INVENTION The present invention relates to a novel therapeutic agent for eel disease, and more particularly to a therapeutic agent for eel disease having an excellent effect on bacterial elasis.
近年、ウナギの疾病のうち細菌性エラ病は、品質低下
した飼料の使用や過密養殖などが原因して増加の傾向を
たどり、ウナギの魚病被害額約28億円のうちの34％を占
めるまでに至つている。その病原菌はFlexibacter col
umnarisといわれ、その治療には１％食塩水やフラゾリ
ドンのようなフラン剤が主に使われている。しかしなが
ら、食塩の場合には、養殖池において使用する際に多量
を必要とすると共に、完全に溶解するために手数がかか
るなどの問題点があり、またフラン剤の場合には、有効
性はよく知られているが、発癌性などの安全性に問題が
あつた。In recent years, bacterial illness among eel diseases has been on the rise due to the use of degraded feed and overcrowding, accounting for 34% of the eel fish disease damage of about 2.8 billion yen. Up to. The pathogen is Flexibacter col
It is called umnaris, and its treatment mainly uses furans such as 1% saline and furazolidone. However, in the case of salt, there is a problem that a large amount is required when used in a culture pond, and it takes time and effort to completely dissolve the salt, and in the case of furan, the effectiveness is good. Although known, there was a problem with safety such as carcinogenicity.
本発明者らは、このような現状にかんがみ、ウナギの
細菌性エラ病治療に有効な薬剤を開発せんと鋭意研究を
行つた結果、亜塩素酸塩が極めて低濃度で前述のFlexib
acter columnarisに対し殺菌作用を示し、当該菌に感
染したウナギのエラ病に卓越した治療効果を有すること
を見いだし、本発明を完成した。In view of this situation, the present inventors have conducted intensive research to develop a drug effective for the treatment of bacterial elastosis in eel.
The present invention was found to have a bactericidal action against acter columnaris and to have an excellent therapeutic effect on eel disease of eel infected with the bacterium, and thus completed the present invention.
すなわち、本発明は、亜塩素酸塩を有効成分として含
有するウナギの細菌性エラ病治療剤を提供するものであ
る。That is, the present invention provides a therapeutic agent for bacterial elastosis of eel, which contains chlorite as an active ingredient.
本発明で使用する亜塩素酸塩としては、例えば亜塩素
酸のアルカリ金属塩、アルカリ土類金属塩が挙げられる
が、このうちアルカリ金属塩のナトリウム、カリウム塩
が好ましい。これら亜塩素酸塩のうち、亜塩素酸ナトリ
ウムは食品添加物として指定されており、安全性も明ら
かにされている物質である。The chlorite used in the present invention includes, for example, alkali metal salts and alkaline earth metal salts of chlorite, and among them, sodium and potassium salts of alkali metal salts are preferable. Among these chlorites, sodium chlorite is designated as a food additive and is a substance whose safety has been clarified.
亜塩素酸塩の濃度については、特に制限はないが、0.
1〜100ppm、好ましくは１〜10ppm程度の濃度になるよう
飼育水または薬浴水に加えればよい。また、本発明の溶
液を罹病ウナギに接触させる方法や時間についても特に
制限はなく、症状の程度に応じて適宜行えば良い。例え
ば、症状が軽度の場合には薬浴水中で１〜２時間、症状
が進行している場合には飼育水中５〜10時間程度接触さ
せれば良い。There is no particular limitation on the concentration of chlorite, but 0.1
It may be added to breeding water or medicine bath water so as to have a concentration of 1 to 100 ppm, preferably about 1 to 10 ppm. The method and time for bringing the solution of the present invention into contact with diseased eel are also not particularly limited, and may be appropriately performed according to the degree of symptoms. For example, when the symptom is mild, it may be contacted for about 1 to 2 hours in the medicine bath water, and when the symptom is progressing, it may be contacted for about 5 to 10 hours.
本発明における治療の対象となるウナギの種類として
は、ニホンウナギ、ヨーロツパウナギ、ヤツメウナギ、
オオウナギ、フイリピンウナギ、ニユージランドウナ
ギ、アメリカウナギなど国内で飼育もしくは棲息する各
種ウナギ類等が挙げられる。The types of eels to be treated in the present invention include Japanese eels, European eels, lampreys,
Various types of eels bred or inhabited in Japan such as eels, Philippine eels, New Zealand eels, and American eels.
本発明のウナギの細菌性エラ病治療剤は、極めて低濃
度で使用することができ、かつ特殊な施設を要せず、従
来の飼育環境に加えることにより目的を達成できる。The therapeutic agent for bacterial eel disease of eel of the present invention can be used at an extremely low concentration, does not require special facilities, and can achieve its purpose by being added to a conventional breeding environment.
次に実施例を挙げて説明する。 Next, an example will be described.
実施例１ 50容パンライト水槽２つを用意し、それぞれに24℃
の飼育水20を加え、平均体重34.0gのニホンウナギ40
尾ずつを収容した（試験区および対照区）。両区に生菌
数106/mlのFlexibacter columnarisを加え、感染させ
た。感染１時間後、試験２区に亜塩素酸ソーダを5ppmに
なるように加え、８時間後に感染魚を24℃の流水槽に移
し、感染水槽内の生菌数の変化および生存状況を経時的
に観察した。亜塩素酸ソーダ無添加の対照区についても
同様に行つた。Example 1 Two 50-volume panlight aquariums were prepared, each at 24 ° C.
Of breeding water 20 and Japanese eel 40 with an average weight of 34.0 g
Each tail was housed (test and control). Flexibacter columnaris having a viable cell count of 10 6 / ml was added to both sections for infection. One hour after infection, sodium chlorite was added to test 2 section to 5 ppm, and 8 hours later, the infected fish was transferred to a water tank at 24 ° C. Was observed. The same procedure was performed for the control group without sodium chlorite.
生菌数に関し、対照区は経時的に横這い、もしくはや
や増加の傾向を示し８時間後には107程度になつたのに
対し、試験区は経時的に激減し、８時間後には検出限界
以下になつた。生存状況に関し、試験区はエラ病に起因
してへい死していくため経時的に減少して、８時間後に
は２尾となつたのに対し、試験区は全尾健全であつた。Regarding the viable cell count, the control plot showed a tendency to level off or slightly increase over time and reached about 10 7 after 8 hours, whereas the test plot drastically decreased over time and was below the detection limit after 8 hours. It has become. Regarding the survival status, the test plot decreased over time due to mortality due to gill disease, and after 8 hours, 2 fish were found, whereas the test plot was healthy.
実施例２ 30容パンライト水槽２つ（対照区および試験区）を
用意し、それぞれに24℃の飼育水10を加え、平均体重
35.0gのエラ病に罹病したヨーロツパウナギ20尾ずつを
収容した。試験区には亜塩素酸ソーダを10ppmになるよ
うに加え、10時間放置した。後、24℃の流水槽に移し、
生存状況を亜塩素酸ソーダ無添加の対照区と比較観察し
た。Example 2 Two 30-volume panlight tanks (control section and test section) were prepared, and breeding water 10 at 24 ° C. was added to each tank.
Twenty 35.0 g of European eels affected with gill disease were housed. Sodium chlorite was added to the test plot to 10 ppm and left for 10 hours. After that, transfer to a running water tank at 24 ° C,
The survival status was compared and observed with the control group without sodium chlorite addition.
１週間後、対照区は全尾へい死したのに対し、試験区
は１尾へい死したにとどまつた。One week later, the control group died in one tail, while the test group died in one tail.
Claims (1)
ギの細菌性エラ病治療剤。1. A therapeutic agent for bacterial elastosis of eel, comprising chlorite as an active ingredient.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP63208837A JP2722214B2 (en) | 1988-08-23 | 1988-08-23 | Eel disease treatment |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP63208837A JP2722214B2 (en) | 1988-08-23 | 1988-08-23 | Eel disease treatment |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JPH0259524A JPH0259524A (en) | 1990-02-28 |
| JP2722214B2 true JP2722214B2 (en) | 1998-03-04 |
Family
ID=16562924
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP63208837A Expired - Fee Related JP2722214B2 (en) | 1988-08-23 | 1988-08-23 | Eel disease treatment |
Country Status (1)
| Country | Link |
|---|---|
| JP (1) | JP2722214B2 (en) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP4684708B2 (en) * | 2005-03-31 | 2011-05-18 | 学校法人加計学園 | Fishery water treatment equipment |
| JP5114014B2 (en) * | 2006-03-29 | 2013-01-09 | 日本カーリット株式会社 | Sodium chlorite injection device for fishery fishery |
| JP2007259808A (en) * | 2006-03-29 | 2007-10-11 | Japan Carlit Co Ltd:The | Method for improving hatching rate of fertilized egg of fish and shellfish |
| JP5711846B1 (en) * | 2014-10-21 | 2015-05-07 | 助川化学株式会社 | Water mold control method in aquaculture water |
-
1988
- 1988-08-23 JP JP63208837A patent/JP2722214B2/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| JPH0259524A (en) | 1990-02-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Woo | Cryptobia (Trypanoplasma) salmositica and salmonid cryptobiosis | |
| Plumb et al. | Necrosis and bacterial infection in channel catfish (Ictalurus punctatus) following hypoxia | |
| CA1218931A (en) | Anti-viral compositions | |
| JP4105535B2 (en) | Antiviral substance | |
| JP2722214B2 (en) | Eel disease treatment | |
| Wiznitzer et al. | On the relation of the size of the intraintestinal pool of endotoxin to the development of irreversibility in hemorrhagic shock | |
| Smith et al. | X-irradiation in hamsters, and effects of streptomycin and marrow-spleen homogenate treatment | |
| Jones et al. | Cryptococcosis of the heart | |
| Bingle et al. | Fatal self-poisoning with phenformin. | |
| CA2162877C (en) | Monohydrate dextrose or glucose composition | |
| Hierholzer et al. | Colorado tick fever pericarditis | |
| Novak et al. | Mebendazole and the development of Hymenolepis nana in mice | |
| Lina et al. | The role of alkalizing and neutral potassium salts in urinary bladder carcinogenesis in rats | |
| US3551566A (en) | Fish disease treating composition and method of using same | |
| JPH08259462A (en) | Antiparbovirus infectious disease composition | |
| Henriksen | Diagnosis and treatment of disease in the turtle | |
| JP3002709B1 (en) | Preventive / therapeutic agent for cold water disease and method for its prevention / treatment | |
| Sarker et al. | The presence of bicarbonate in oral rehydration solution does not influence fluid absorption in cholera | |
| Douglas et al. | The treatment of paraquat poisoning: three cases of recovery. | |
| CA1120402A (en) | Preparation and method for treatment of hypocalcemia, hypophosphatemia and downer cow syndrome in animals | |
| Cleghorn et al. | Activity of desoxycorticosterone acetate in propylene glycol by oral and intravenous routes in adrenalectomized dogs, and its effect on the cardiac arhythmia of adrenal insufficiency | |
| RU2377995C1 (en) | Method for treatment of calves suffering from dyspepsia with correction of pathological thrombocyte activation | |
| David et al. | The Toxicity and Balantidicidal Action of “Di-Hydranol” in Guinea Pigs. | |
| Smith | Fluid therapy in adult cattle. | |
| CA1214993A (en) | Means for medicinal treatment and metaphylaxis of urate and mixed urate lithiase |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| LAPS | Cancellation because of no payment of annual fees |